论文部分内容阅读
Cancer chemoprevention approaches generally use long-term, continuous treatment, which can produce major preventive effects but which can also have unexpected serious adverse events.This raises the question of whether intermittent dosing schedules might reduce toxicity while retaining benefit, a concept that we call shortterm intermittent therapy to eliminate premalignancy (SITEP).Recent preclinical studies support a novel SITEP approach whereby shortterm, intermittent therapy eliminates premalignant cells via apoptosis that is induced by synthetic lethal interactions.